
The 1st International Online Conference by Antibodies
Therapeutic Antibodies: New Trends in Discovery, Developability and Characterization
Part of the International Online Conference on Antibodies series
13–14 October 2025



Antibody Discovery, Antibody Engineering, Antibody Function, Antibody Therapeutics, Antibody Diagnostics, Humoral Immunity
- Go to the Sessions
- Event Details
The Abstract Submission Deadline is closed. Register here by 9 October to participate to the Live Session!
Register for FREE to IOCAB 2025, which will take place on 13—14 October 2025!
Welcome from the Chair
Discovered more than hundred years ago, antibodies have emerged as the most versatile and therapeutically effective class of biological drugs that we currently have. Since the approval of the first therapeutic antibody, muromonab-CD3, by the U.S. Food and Drug Administration (FDA) in 1986, and also the subsequent approval of the first recombinant humanized antibody, trastuzumab, in 1998, the number of monoclonal (or recombinant) antibodies (mAbs) in clinical use has grown exponentially, currently accounting for more than half of the top ten drugs according to global sales.
- Antibody Discovery and Engineering;
- Antibody-based Therapeutics;
- Immuno-oncology and Tumor Imaging;
- Humoral Immunity;
- Computational Antibody Engineering.
Professor Arne Skerra
School of Life Sciences, Technical University of Munich, Munich, Germany
Program Overview
13 October- Morning 9 AM CEST |
14 October- Morning 9 AM CEST |
Session 2. Antibody-based Therapeutics |
Session 1. Antibody Discovery and Engineering |
13 October - Afternoon 2 PM CEST |
14 October - Afternoon 2 PM CEST |
Session 4. Humoral Immunity & |
Session 5. Computational Antibody Engineering |
IOCAB 2025 Program (DAY 1)
Session 2. Antibody-based Therapeutics
Date: 13 October 2025 (Monday)
Time: 9:00 (CEST, Basel) | 03:00 (EDT, New York) | 15:00 (CST Asia, Beijing)
CEST |
Speaker |
Title |
9:00–9:20 |
Prof. Dr. Arne Skerra |
Welcome and Opening Remarks |
9:20–9:30 |
Dr. Patrick Chames |
Welcome from the Session Chair |
9:30–10:00 |
Prof. Dr. Stefan Dübel |
Remotely controlled Antibodies |
10:00–10:25 |
Dr. Thomas Böldicke |
Recombinant Antibodies and Recombinant T-cells against Intracellular Neoantigens |
10:25–10:40 |
Ainhoa Goenaga Aramendi |
Antibody-Functionalized Nanoparticles: A Targeted Drug Delivery Strategy |
10:40–10:55 |
Salman Shahid |
Cryo-EM Structures of HCV E2 Bound to Neutralizing and Non-Neutralizing Antibodies Using Engineered Domain-Swapped Bivalent Fabs as Fiducial Markers |
10:55–11:00 |
Inesa Stonkutė |
Predictive Biomarkers for Monoclonal Antibody Therapy Response in Oral Squamous Cell Carcinoma: A Systematic Review |
11:00–11:05 |
Archana Damavarapu |
Role of Antibodies in HAV Vaccines and Therapeutic Approaches: Insights into Immunological Strategies |
11:05–11:10 |
Empuluri Haritha |
Antibodies Involved in Allergic Conditions: Mechanisms and Therapeutic Insights |
11:10–11:15 |
Palla Nikitha Selected Poster Presenter |
Antibody-Drug Conjugates: Redefining Chemotherapy with Targeted Precision |
11:15–11:20 |
Peruri Likitha Selected Poster Presenter |
Targeted Drug Delivery in Lung Cancer Using Antibodies: A Precision Approach to Therapy |
11:20–11:25 |
Chinthu Krishnaveni Selected Poster Presenter |
Architects of Immunity: Structural Insights into Antibodies for Novel Biomedical Applications |
11:25–11:30 |
Aluru Uma Priyanka Selected Poster Presenter |
Advancements in Antibody Technology: From Bispecifics to AI-Driven Therapeutics |
11:30–14:00 |
Break |
Session 4. Humoral Immunity
Session 3. Immuno-oncology and Tumor Imaging
Date: 13 October 2025 (Monday)
Time: 14:00 (CEST, Basel) | 08:00 (EDT, New York) | 20:00 (CST Asia, Beijing)
CEST |
Speaker |
Title |
14:00–14:10 |
Dr. Cecile King |
Welcome from Session Chair |
14:10–14:40 |
Professor Guglielmo Lucchese Invited Speaker |
Autoantibodies in post-COVD-syndrome |
14:40–14:45 |
Madalen Arribas Galarreta Selected Poster Presenter |
A broad-spectrum SARS-CoV-2 immunization strategy targeting the highly conserved MPER of the Spike protein |
14:45–14:55 |
Professor Sophia Karagiannis |
Welcome from Session Chair |
14:55–15:25 |
Prof. Dr. Nick Devoogdt Keynote Speaker |
Imaging tumor immunity with nanobody tracers: from camel to bedside |
15:25–15:55 |
Prof. Dr. Christian Klein |
The present and future of bispecific antibodies for cancer therapy |
15:55–16:20 |
Volker Morath |
PET Tracking of Cell and Gene Therapies Using a Novel Lanthanide•DTPA-Binding Anticalin Reporter Gene |
16:20–16:25 |
Krishnaveni Manubolu |
Targeting the Tumor Microenvironment with Radiolabeled Antibodies: Bridging Immunotherapy and Molecular Imaging |
IOCAB 2025 Program (DAY 2)
Session 1. Antibody Discovery & Engineering
Date: 14 October 2025 (Tuesday)
Time: 9:00 (CEST, Basel) | 03:00 (EDT, New York) | 15:00 (CST Asia, Beijing)
CEST |
Speaker |
Title |
9:00–9:10 |
Prof. Dr. Serge Muyldermans |
Welcome from the Session Chair |
9:10–9:40 |
Prof. Dr. Harald Kolmar |
Discovery and optimization of bispecific antibodies with prescribed binding characteristics and biophysical properties |
9:40–10:10 |
Professor Shohei Koide |
Creating and targeting cancer-specific neoantigens by design |
10:10–10:35 |
Professor Jan Steyaert |
Engineering Nanobodies for structural Biology, molecular pharmacology and drug discovery |
10:35–11:00 |
Alessa Schaffrath |
Selection of nanobodies from LamaMice |
11:00–11:05 |
Mattias Collin |
Chemoenzymatically glycan engineered monoclonal IgG antibodies against Streptococcus pyogenes |
11:05–14:00 |
Break |
Session 5. Computational Antibody Engineering
Session 4. Humoral Immunity
Date: 14 October 2025 (Tuesday)
Time: 14:00 (CEST, Basel) | 08:00 (EDT, New York) | 20:00 (CST Asia, Beijing)
CEST |
Speaker |
Title |
14:00–14:10 |
Prof. Dr. Arne Skerra |
Welcome from Event Chair |
14:10–14:40 |
Prof. Dr. Sai Reddy |
Generative design of antibody Fc variants with synthetic and programmable immune function |
14:40–15:10 |
Dr. Pietro Sormanni Keynote Speaker |
Antibody discovery and engineering by computational design |
15:10–15:15 |
Sümeyla Ceren Elmaci |
Computational Nanobody Design for Amyloid-Beta 42 Octamer in Alzheimer’s Disease |
15:15–15:45 |
Prof. Dr. Christoph Schmidt |
Undue complement activation: Therapeutic strategies and hidden pitfalls |
15:45–15:50 |
Prof. Dr. Arne Skerra Event Chair |
Closing Remarks |
Event Chair

School of Life Sciences, Technical University of Munich, Munich, Germany
Following chemical studies at TU Darmstadt, Prof. Skerra obtained a doctorate at the Gene Centre of Munich’s Ludwig Maximilians University in 1989 and completed his lecturer qualification in biochemistry at the University of Frankfurt am Main in 1995. Before his appointment as full professor at TUM, he was professor of protein chemistry at TU Darmstadt from 1994 to 1998. Prof. Skerra is founder of Pieris Pharmaceuticals, Inc. (Nasdaq: PIRS) and XL-protein GmbH. In 2008, he was elected to the National Academy of Science and Engineering (acatech). Prof. Skerra engages research in the field of protein engineering and design. The focus of his work is on the construction of artificial binding proteins and enzymes with novel, tailored functions, in particular for applications in medical and industrial biotechnology. Rational and combinatorial research approaches are pursued in tandem with protein biochemical and spectroscopic methods as well as protein crystallographic analyses. Several technologies from his laboratory have entered commercialization: Strep-tag®, Anticalin® proteins and PASylation®.
Keynote Speakers

Department of Biotechnology, Technical University of Braunschweig, Braunschweig , Germany
Session 2. Antibody-based Therapeutics
Stefan Dübel is Full Professor of Biotechnology and Director of the corresponding department at the Technical University of Braunschweig, Germany. He also heads the technology transfer office "Center for Molecular Engineering" at iTUBSmbH and works as a consultant for biotech/pharmaceutical companies and US/EU government institutions. His research topics are Antibody Engineering, Phage Display, Animal-Free Antibody Generation, Anti-Cancer-Antibodies, Intrabodies, in vitro Evolution, Synthetic Biology, Biosensors, Hyperphage, SARS-CoV-2 neutralizing antibodies.

Clemens Schöpf-Institute of Chemistry and Biochemistry, Technical University of Darmstadt, Darmstadt, Germany
Session 1. Antibody Discovery and Engineering
Harald Kolmar is full professor of Biochemistry at the Technische Universität Darmstadt. His current scientific interests mainly focus on protein engineering and design, nanobiotechnology, antibody engineering, chemical biology and development of tailor-made peptides and miniproteins for applications in diagnostics and therapy. His research interests are Peptides, Protein Engineering, Biochemistry, Protein Expression, Biotechnology, Proteins and Recombinant Fusion Proteins.

Session 3. Immuno-oncology and Tumor Imaging
Dr. Christian Klein is Distinguished Scientist and Department Head Cancer Immunotherapy Discovery at the Roche Innovation Center Zurich, specialized in the discovery, validation and preclinical development of antibody-based cancer immunotherapies and bispecific antibodies. During his 16 years at Roche he has made major contributions to the development and approval of obinutuzumab, the preclinical development of currently nine clinical stage bispecific antibodies/antibody fusion proteins, and the development of Roche’s proprietary bispecific antibody platforms e.g. the CrossMAb technology and immunocytokine and T-cell bispecific antibody platforms. 2017 he completed his habilitation in biochemistry at the Ludwig-Maximilians University Munich and acts as external lecturer there.
The present and future of bispecific antibodies for cancer therapy

Session 3. Antibody-based Diagnostics
I obtained a MSc degree in Molecular Biology in 1997 and a PhD degree in Applied Biological Sciences in 2004, both at the Free University Brussels, working on cancer genetics and investigating the interaction between cancer cells and tumor-infiltrating macrophages. After my PhD, in 2004-2005, I joined a team at the USA National Cancer Institute in Bethesda, Maryland to study ovarian cancer genetics. I returned to the Free University Brussels to fulfill a number of postdoc positions, at first continuing my research on cancer genetics and the interplay between cancer cells and their microenvironment. During these studies I got acquainted with antibody engineering and became skilled in the art of nanobody technology. From 2007 on I started to apply nanobodies as tracers for molecular imaging. Currently I'm a full professor heading a team at the Free University Brussels applying nanobodies as vehicles for imaging and therapy in the fields of oncology, inflammation and cardiovascular diseases.

Department of Biosystems Science and Engineering, ETH Zurich, Zurich, Switzerland
S5. Computational Antibody Engineering
Sai Reddy is an Associate Professor of Systems and Synthetic Immunology at ETH Zurich in the Department of Biosystems Science & Engineering (D-BSSE, Basel, Switzerland). He is the principal investigator of the Laboratory for Systems and Synthetic Immunology. Systems immunology uses quantitative measurements, computational biology and machine learning to describe and understand the complexity of the immune system. His group has developed a number of methods in systems immunology to greater understand adaptive immunity, in particular with a focus on antibody repertoire sequencing and analysis. Synthetic immunology is based on using methods in molecular and cellular engineering to control immune cell function and behavior. His group has established methods to reprogram immune cells for applications in directed evolution and cellular immunotherapy, with an emphasis on engineering the immunogenome.

Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, UK
S5. Computational Antibody Engineering
Dr Pietro Sormanni is a group leader supported by a Royal Society University Research Fellowship. His research focuses on the development of innovative data-driven technologies of rational antibody design, to obtain antibodies against targets that have been challenging to access using conventional approaches, and to improve or predict biophysical properties crucial for the successful development of antibody therapeutics. In his work he has established numerous collaborations and industrial partnerships, whose outcomes are beginning to demonstrate that computational approaches can be applied alongside established procedures to streamline antibody development, and to offer time- and cost-effective novel alternatives. Prior to taking up this post, Pietro held a postdoctoral Borysiewicz Biomedical Sciences Fellowship from the University of Cambridge, obtained a PhD in Chemistry from the University of Cambridge, and an MSc in Theoretical Physics from the University of Milan.

Department of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, New York, USA
S1. Antibody Discovery & Engineering
Shohei Koide, Ph.D. is a synthetic protein scientist. His research integrates mechanistic biochemistry and directed evolution to create highly functional but still simple proteins. He is the inventor of the FN3 Monobody technology, and has made important contribution to synthetic antibody technologies. He has pioneered many applications of synthetic binding proteins to biology, chemistry and medicine. Previously he was Professor at University of Chicago and at University of Rochester School of Medicine and Dentistry. He is an elected fellow of the AAAS and the National Academy of Inventors. He is a co-founder of Aethon Therapeutics.

Institute of Experimental and Clinical Pharmacology, Toxicology and Pharmacology of Natural Products, University of Ulm Medical Center, Ulm, Germany
S4. Humoral Immunity
Dr. Christoph Schmidt is a Professor of Experimental Pharmacology at the Institute of Experimental and Clinical Pharmacology, Toxicology and Pharmacology of Natural Products, University of Ulm Medical Center. He studied pharmaceutical sciences at the LMU Munich (Germany) and received his Ph.D. at the University of Edinburgh (United Kingdom; under the guidance of Prof. Barlow), working on the structure and function of the complement regulator factor H. After his studies, Dr. Schmidt moved to the US for his postdoc, where he worked at the Innate Immunity/protein Chemistry laboratory (under the guidance of Prof. Lambris), focusing on developing a complement inhibitor. Since 2017 he has been a group leader at the Institute of Pharmacology of Natural Products and Clinical Pharmacology at Ulm University in Germany. After a short stay as a Professor of Biochemical Pharmacy at the Martin-Luther University of Halle-Wittenberg, he was appointed Professor of Experimental Pharmacology at the University of Ulm Medical Center. He and his team use numerous techniques to investigate the complement system to design new therapeutic molecules. His work has made fundamental contributions to the complement field, which includes extensive work on how the cascade is organized and regulated.
Invited Speakers

Department of Experimental Medicine, University of Salento, Lecce, Italy
S4. Humoral Immunity
I received my MD from the University of Bari in 2009. There I practiced as a physician in the Neurophysiopathology Unit and did biomedical research, with a particular focus on multiple sclerosis. In 2012 I joined the Brain Language Lab and started my Ph.D. in Neuroscience of Language. My research deals with clinical, physiological and molecular aspects of brain (dis)function ranging across neuroepidemiology, neuropharmacology, immunology, and - more recently - neurophysiology and cognitive neuroscience. Current research interests: syntactic and semantic processing in auditory language perception, aphasia and language impairments and electroencephalography (EEG) and event related potentials (ERPs).

S2. Antibody-based Therapeutics
Associate Professor Dr. Thomas Böldicke received his PhD 1982 at the Max-Planck-Institut of Molecular Genetics, Berlin. He started his carrier as post doc at the German Research Centre for Biotechnology (GBF, Braunschweig, Germany) in the Department of Genetics and Cell Biology by John Collins. Now he is senior scientist at the Helmholtz Centre for Infection Research (HZI, former GBF) and project leader intrabodies. He developed recombinant antibodies against tumor antigens, particularly against tumour angiogenesis, rhabdyomyosarcoma and recently against TLR2 and TLR9 in pancreatic cancer. He edited two books: “Protein Targeting Compounds” with Springer (2016) and “Antibody Engineering” with IntechOpen (2017). He has published 25 Pubmed manuscripts. Over 10 years he gave lectures at the Technical University in Braunschweig about immunology, cancer development and immunotherapies. He is in the editorial board of the journal Antibodies as academic editor, Frontiers in Immunology and Frontiers in Oncology.

University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Department of Bio-engineering Sciences, Vrije University of Brussel, Brussel, Belgium

Clinic and Polyclinic for Nuclear Medicine, Technical University of Munich, Munich, Germany
PET Tracking of Cell and Gene Therapies Using a Novel Lanthanide•DTPA-Binding Anticalin Reporter Gene
Session Chairs

Dr. Patrick Chames
Cancer Research Center of Marseille, Marseille, France
Patrick Chames obtained his phD at the Aix Marseille University, France in 1997 in the field of antibody engineering. From 1997 to 2001, he worked in the laboratory of phage display pioneer Hennie R. Hoogenboom where he isolated by phage display the first human antibody fragment specifically binding to a cancer-related class I MHC complex (TCR-like antibodies). From 2001 to 2005, he worked for a french start-up company (Cellectis SA, Paris) in the field of genome engineering where he significantly contributed to the set up of an in vivo method, leading to the isolation of homing endonucleases capable of performing specific double strand break in a whole genome. In 2005 he accepted a permanent position for the French National center for research (CNRS). Since 2009, he is working in the field of multispecific antibodies for cancer immunotherapy and is specialized in the use of single domain antibodies. Since 2012 he is leading the Antibody Therapeutics and Immunotargeting (ATI) team, part of the Cancer Research Center of Marseille (CRCM).

Professor Sophia Karagiannis
St. John’s Institute of Dermatology, School of Basic & Medical Biosciences, London, UK
Sophia Karagiannis is a translational cancer immunologist with academic and biotechnology experience in the USA and UK. She heads a cancer antibody discovery team focused on dissecting the crosstalk between patient immune cells and cancer and on the design of novel agents for solid tumours such as melanoma, ovarian and breast cancers. Key areas of research include evaluating patient-derived B cells and their expressed antibodies, engineering antibodies of any specificity or class/isotype, including Fc-engineered antibodies and antibody-drug conjugates. The group are studying key components of the immune response in solid tumours, including Fc receptor-expressing immune effector cells which interact with and have the potential to be activated by antibodies against cancer.

Prof. Dr. Serge Muyldermans
Department of Biotechnology, Vrije Universiteit Brussel, Brussel, Belgium
Graduated as Chemist at Vrije Universiteit Brussel, Brussels, Belgium in September 1977 PhD at Vrije Universiteit Brussel, Brussels, Belgium in June 1982 with greatest distinction. The structural organization of chromatosomes (nucleosomes), the subunit of chromatin, (i.e. DNA and histone proteins as occurring in the nucleus of eukaryotes) was investigated for the Ph D dissertation. This topic remained the main research focus afterwards as well and led to several publications in Nucleic Acids Research, J. Mol. Biol, Biochemistry, J.Biol. Chem and a publication in Nature (1998). As a postdoc with skills in cloning, DNA sequencing and genetic engineering Dr Serge Muyldermans switched the focus of his research towards camel heavy chain antibodies as a result of their serendipitous discovery in the laboratory at Vrije Universiteit Brussel. He developed a technology to generate and identify the unique single domain antigen binding fragments (referred to as Nanobodies) of these heavy chain-only antibodies. This technology became the core of Ablynx spin-off of which he was co-founder (2002).

Dr. Cecile King
School of Biotechnology and Biomolecular Sciences at the University of New South Wales Sydney, Sydney, Australia
Associate Professor Cecile King, Ph.D., joined the School of Biotechnology and Biomolecular Sciences at the University of New South Wales Sydney in 2021. CK received her Ph.D. in Immunology from UWA and completed her postdoctoral training at the Scripps Research Institute, La Jolla, USA. She joined the faculty of the Garvan Institute for Medical Research, Sydney, Australia in 2005. CK continues to be intrigued by how the immune system maintains tolerance to self and has made important contributions to our understanding of adaptive immune responses and autoimmunity. CK’s current research focus is RNA at the immune interface: Understanding both immune recognition of RNA and immune regulation by non-coding RNA and transposable elements.
Event Committee

Department of Microbiology & Immunology, The University of Texas Medical Branch, Texas, USA

Institute of Molecular Biotechnology, Boku University, Wien, Austria

Department of Biosciences, Nihon University, Tokyo, Japan

SKumar Biotech Advisory LLC, Sumter, USA

Department of Pharmaceutics, Ernest Mario School of Pharmacy Rutgers, The State University of New Jersey, Piscataway, USA

Department of Pharmacy-Pharmaceutical Sciences, University of Bari, Bari, Italy

Department of Medicine, Harvard Medical School, Boston, USA
Registration
Instructions for Authors
Important Deadlines
- Deadline for abstract submission: 15 July 2025 15 August 2025
- Announcement of oral and poster abstract results: 11 August 2025 15 September 2025. You will be notified of the acceptance of an oral/poster presentation in a separate email.
Certificates of Participation are available in your logged-in area of Sciforum.net, under “My Certificates” after the conference.
1. The abstract structure should include the introduction, methods, results, and conclusions sections of about 200–300 words in length.
2. All abstracts should be submitted and presented in clear, publication-ready English with accurate grammar and spelling.
3. You may submit multiple abstracts. However, only one abstract will be selected for oral presentation.
Detailed Requirements:
1. The submitting author must ensure that all co-authors are aware of the contents of the abstract.
2. Please select only one presenter for each submission. If you would like to change the presenter after submission, please email us accordingly.
Note: We only accept live presentations.
The slot for the oral presentation is 15 mins. We advise that your presentation lasts for a maximum of 12 mins, leaving at least 3 mins for the Q&A session. Authors are encouraged to prepare a presentation in PowerPoint or similar software, to be displayed online along with the abstract. Slides, if available, will be displayed directly on the website using the proprietary slide viewer at Sciforum.net. Slides can be prepared in exactly the same way as for any traditional conference where research results are presented. Slides should be converted to PDF format prior to submission so that they can be converted for online display.
- Poster should include the title, authors, contact details and main research findings, as well as tables, figures and graphs where necessary.
- File format: PDF (.pdf).
- Size in pixel: 1080 width x 1536 height–portrait orientation.
- Size in cm: 38,1 width x 54,2 height–portrait orientation.
- Font size: ≥16.Examples of successful submissions can be viewed here at the following links: (1), (2), (3).
You can use our free template to create your poster. The poster template can be downloaded HERE.
Authors who wish to present a poster are invited to send it to the conference email at iocab2025@mdpi.com. All posters will be permanently exhibited online in the Poster Gallery.
It is the author's responsibility to identify and declare any personal circumstances or interests that may be perceived as inappropriately influencing the representation or interpretation of clinical research. If there is no conflict, please state "The authors declare no conflicts of interest." This should be conveyed in a separate "Conflicts of Interest" statement preceding the "Acknowledgments" and "References" sections at the end of the manuscript. Any financial support for the study must be fully disclosed in the "Acknowledgments" section.
MDPI, the publisher of the Sciforum.net platform, is an open access publisher. We believe authors should retain the copyright to their scholarly works. Hence, by submitting an abstract to this conference, you retain the copyright to the work, but you grant MDPI the non-exclusive right to publish this abstract online on the Sciforum.net platform. This means you can easily submit your full paper (with the abstract) to any scientific journal at a later stage and transfer the copyright to its publisher if required.
Publication Opportunities
Participants in this conference are cordially invited to contribute a full manuscript to the conference's Special Issue "Selected Papers from The 1st International Online Conference by Antibodies 2025", published in Antibodies (ISSN 2073-4468, Impact Factor 2.7), with a 20% discount on the publication fee. Please note that no other discounts are applicable. All submitted papers will undergo MDPI’s standard peer-review procedure. The abstracts should be cited and noted on the first page of the paper.
All accepted abstracts will be published in the conference report of The 1st International Online Conference on Antibodies in journal Medical Sciences Forum (ISSN: 2673-9992); if you wish to publish an extended proceeding paper (4—8 pages), please submit it to the same journal after the conference. There will be no additional fees.
Proceedings submission deadline: 24 November 2025.
Manuscripts for the proceedings issue must be formatted as follows:
Title;
Full author names;
Affiliations (including full postal address) and authors' e-mail addresses;
Abstract;
Keywords;
Introduction;
Methods;
Results and Discussion;
Conclusions;
Acknowledgements;
References.
IOCAB 2025 Proceeding Paper Template
List of accepted submissions (30)
Id | Title | Authors | |||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
sciforum-145186 | Detection of Anti-HEV IgM and IgG Antibodies among Antenatal Women Attending a Tertiary Care Center | , , |
Show Abstract |
||||||||||||||||||||||||||||||||||||||
Hepatitis E virus (HEV) is recognized as one of the leading causes of acute viral hepatitis (AVH) in developing countries, where it is primarily transmitted through the consumption of contaminated food and water. Although often self-limiting, HEV infection poses a significant public health concern, particularly among pregnant women, due to its potential complications. The present study aimed to determine the seroprevalence of HEV infection in asymptomatic antenatal women attending a tertiary care center in South Punjab, Pakistan. A total of 100 asymptomatic pregnant women were screened for anti-HEV antibodies (IgM and IgG) using an ELISA kit (DIA PRO, Italy). The overall seropositivity rate was found to be 12%, indicating prior exposure to HEV infection in this cohort. Specifically, IgG antibodies were detected in 6% of women and IgM antibodies in 5%, while two women showed evidence of both IgG and IgM positivity, suggestive of recent or ongoing infection. Notably, the majority of participants reported reliance on untreated water sources irrespective of educational background, highlighting environmental risk factors. Although HEV is generally self-limiting, these findings underscore the importance of routine serological screening in antenatal populations to prevent adverse pregnancy outcomes. In addition, increased community awareness regarding transmission routes and preventive measures is essential. Given the scarcity of regional data, this study emphasizes the need for larger-scale epidemiological investigations to better understand the burden of HEV in South Punjab, Pakistan. Keywords: Hepatitis E Virus, Antenatal Women, Seroprevalence, Immunoglobulins, South Punjab |
|||||||||||||||||||||||||||||||||||||||||
sciforum-125772 | Antibody–drug conjugates (ADCs) and their journey to autoimmune disease immunotherapy |
Show Abstract |
|||||||||||||||||||||||||||||||||||||||
Antibody–drug conjugates (ADCs) represent a novel and rapidly evolving class of targeted therapeutics that combine the high specificity of monoclonal antibodies (mAbs) with the potent cytotoxic effects of small-molecule drugs. These engineered molecules are designed to selectively deliver cytotoxic agents to specific cells, thereby reducing off-target toxicity and enhancing therapeutic efficacy. In oncology, ADCs have already demonstrated significant clinical success, particularly in the treatment of hematological malignancies and solid tumors. Agents such as trastuzumab emtansine and brentuximab vedotin exemplify how ADCs can effectively target cancer cells while limiting damage to healthy tissues. Over the past decade, the development of new linkers, payloads, and antibody engineering technologies has further refined the safety and effectiveness of ADCs, leading to an expanded pipeline of approved and investigational compounds. Following their success in oncology, interest has grown in repurposing ADCs for the treatment of non-malignant diseases, including autoimmune disorders. These conditions are characterised by inappropriate immune responses in which autoreactive cells and inflammatory mediators attack host tissues. ADCs offer a promising solution by enabling the selective depletion or modulation of these pathogenic immune cell subsets without broadly suppressing the entire immune system. Preclinical and early clinical studies have shown encouraging results. For instance, ADCs targeting CD19 or CD22 are being explored for systemic lupus erythematosus and other B-cell-driven diseases, while anti-CD3 ADCs have shown potential in type 1 diabetes. As knowledge of disease-specific immune targets increases, ADCs may provide a new avenue for achieving durable remission in autoimmune diseases with improved safety profiles compared to conventional immunosuppressants. This presentation comprehensively explores the evolving landscape of ADCs in autoimmune therapeutics. |
|||||||||||||||||||||||||||||||||||||||||
sciforum-125774 | Development of IgY-Based Vaccine for Salmonella Control in Layer Chickens |
,
Suzette Curtello ,
|
Show Abstract |
||||||||||||||||||||||||||||||||||||||
Salmonella infections in poultry represent a significant public health and economic burden, particularly in regions where poultry serves as a major source of animal protein. Traditional control methods often rely on antibiotics, which contribute to antimicrobial resistance and raise consumer health concerns. This study developed a novel, sustainable strategy by integrating indigenous plant-based bacterial attenuation with immunotherapy using IgY antibodies. Specifically, garlic (Allium sativum) and onion (Allium cepa) extracts were employed to attenuate wild-type Salmonella serovars. These plant-derived agents exhibited strong antimicrobial properties, effectively inhibiting bacterial growth in vitro. The attenuated strains were then used to vaccinate chickens, which led to the induction of high levels of anti-Salmonella IgY antibodies, as confirmed by an enzyme-linked immunosorbent assay (ELISA). Functional assays revealed that the harvested IgY antibodies possessed robust agglutination activity, highlighting their potential role in passive immunisation strategies. Importantly, the vaccine was found to be both safe and immunogenic, with no adverse effects observed in the immunised birds. This dual approach—combining natural antimicrobial agents with immune-based protection—offers a cost-effective and environmentally friendly alternative to conventional methods. It holds particular promise for improving poultry health and food safety in the Caribbean, where locally available resources and affordable interventions are crucial. This strategy may also be applicable to broader global contexts, especially in low-resource agricultural settings. |
|||||||||||||||||||||||||||||||||||||||||
sciforum-127701 | Advances in Tumor Imaging to Effectively Optimize Immuno-oncology Strategies for Ensuring Appropriate Treatment and Patient Well-Being |
Show Abstract |
|||||||||||||||||||||||||||||||||||||||
In the last decade, immuno-oncology has revolutionized cancer therapy by harnessing the body's immune system to target and eliminate tumor cells, offering durable responses particularly in malignancies previously considered treatment-resistant. This approach exploits immune checkpoints, monoclonal antibodies, Chimeric Antigen Receptor (CAR) T-cells, and innovative cancer vaccines to activate, promote, and enhance immune responses specific to tumor-associated antigens. However, the complexity of tumor–immune interactions necessitates advanced tumor imaging techniques to accurately diagnose, monitor, and tailor effective immunotherapy techniques. Tumor imaging plays a pivotal role in visualizing immune cell infiltration, tracking immune responses in real-time, and identifying immune-related adverse events. Recent innovations such as hybrid Magnetic Resonance Imaging (MRI), Computed Tomography (CT), and Positron Emission Tomography (PET) (PET/CT and MRI) combined with novel tracers—like radiolabeled antibodies targeting Programmed Death-Ligand 1 PD-L1—allow precise quantification of immune activation within the tumor microenvironment. These modalities facilitate early assessment of therapeutic efficacy, guiding personalized treatment adjustments. Furthermore, multimodal imaging approaches integrating molecular and anatomical data improve the delineation of tumor boundaries, detect metastases, and evaluate emerging resistance mechanisms. As immuno-oncology moves toward personalized medicine, imaging biomarkers will be essential in stratifying patients most likely to benefit from immune-based therapies, predicting outcomes, and minimizing toxicity. Continued research in tumor imaging will enhance our understanding of immune dynamics, ultimately improving treatment precision and patient survival in cancer care. The main aim of this was to advance and develop the in-depth understanding and application of innovative tumor imaging techniques that accurately visualize and quantify immune responses within the tumor microenvironment. By enabling personalized immunotherapy strategies, improving personalized treatment and monitoring will significantly enhance patient therapeutic outcomes, as a result of appropriate treatment corresponding to effective and modern cancer care. |
|||||||||||||||||||||||||||||||||||||||||
sciforum-129009 | "Next-Generation Antibody Design: Computational Approaches for De Novo Engineering, Affinity Maturation, and Personalized Therapeutics" |
,
Afrodita Doina Marculescu
|
Show Abstract |
||||||||||||||||||||||||||||||||||||||
Novel and developed computational approaches in the field of antibody engineering have revolutionized and leveraged advanced algorithms through machine learning and detailed structural modeling in order to deeply facilitate the de novo design of new, effective therapeutic agents based on antibodies, affinity maturation, and stability optimization, significantly enhancing and accelerating the drug development processes. The main purpose of this paper is to clearly illustrate how advanced computational antibody design techniques, such as de novo engineering, affinity maturation, and personalized modeling, can deeply affect modern and precision therapeutics by enabling the rapid development of highly specific and potent monoclonal antibodies tailored to specific critical diseases. We observed the rapid development of highly specific and potent monoclonal antibodies tailored for some specific critical diseases—particularly cancers; for example, Human Epidermal Growth Factor Receptor 2 (HER2) or Receptor Tyrosine-Protein Kinase erbB-2- positive breast cancer or colorectal cancer. For autoimmune disorders such as Rheumatoid Arthritis (RA), Antikeratin, anticitrullinated peptides, anti-RA33, anti-Sa, and anti-p68 autoantibodies have been shown to have >90% specificity for RA. Regarding infectious diseases, the immunoglobulins lg M, lg A, and lg G are the key players in the response and the fight against COVID-19. The ultimate essential goal consists is to improve therapeutic efficacy, reduce off-target effects, and facilitate specific personalized treatment strategies that effectively address individual patients' molecular profiles. Machine learning algorithms like DeepMind’s AlphaFold have dramatically improved the accuracy of antibody–antigen structure prediction, facilitating the rapid identification of high-affinity binders. In one instance, a computational redesign of an anti-PD-1 (Immune checkpoint inhibitor) antibody enhanced its binding affinity and stability, leading to a more potent immune checkpoint inhibitor for cancer therapy. Moreover, the de novo design of bispecific antibodies has enabled simultaneous targeting of multiple tumor antigens, such as Cluster of Differentiation 3 (CD3) and Epidermal Growth Factor Receptor (EGFR), boosting immune activation in resistant cancers. |
Event Awards
To acknowledge the support of the conference's esteemed authors and recognize their outstanding scientific accomplishments, we are pleased to announce that the conference will provide 6 awards including Best Oral Presentation Awards and Best Poster Awards.
The Awards
Number of Awards Available: 6
The Best Poster Awards are given to the submission judged to make the most significant and interesting poster for the conference.
Sponsors and Partners
For information regarding sponsorship and exhibition opportunities, please click here.
Organizers
Media Partners
Conference Secretariat
Mrs. Theodora Cuci
Mr. Ionut Spatar
Mr. Russell Wang
Email: iocab2025@mdpi.com
For inquiries regarding submissions and sponsorship opportunities, please feel free to contact us.
S1. Antibody Discovery & Engineering
Session Chair
Prof. Dr. Serge Muyldermans, Department of Biotechnology, Vrije Universiteit Brussel, Brussel, Belgium
Show all published submissions (2) Hide published submissions (2)
Submissions
List of Papers (2) Toggle list
S2. Antibody-based Therapeutics
Session Chair
Dr. Patrick Chames, Cancer Research Center of Marseille, Marseille, France
Show all published submissions (17) Hide published submissions (17)
Submissions
List of Papers (17) Toggle list
S3. Immuno-oncology and Tumor Imaging
Session Chair
Professor Sophia Karagiannis, St. John’s Institute of Dermatology, School of Basic & Medical Biosciences, London, UK
Show all published submissions (3) Hide published submissions (3)
Submissions
List of Papers (3) Toggle list
S4. Humoral Immunity
Session Chair
Dr. Cecile King, School of Biotechnology and Biomolecular Sciences at the University of New South Wales Sydney, Sydney, Australia
Show all published submissions (1) Hide published submissions (1)
Submissions
List of Papers (1) Toggle list
S5. Computational Antibody Engineering
Show all published submissions (7) Hide published submissions (7)
Submissions
List of Papers (7) Toggle list